Momentum around women's health treatments is building, and Lipocine Inc. (LPCN) has stepped into the spotlight with its oral brexanolone candidate, LPCN 1154, now advancing through a pivotal Phase 3 program for postpartum depression (PPD). With key clinical milestones approaching in 2026, Lipocine's development efforts highlight its broader commitment to patient-focused innovation in central nervous system disorders.
Shares of the company recently mirrored this progress, closing at $4.20 with a 14.44% gain for the day and edging slightly higher to $4.23 in after-hours trading.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.